Content about Mylan Inc.

WASHINGTON — A federal judge in Washington has dismissed a suit against the FDA brought up by Mylan for withholding approval for the company to sell a generic version of Novartis AG’s heart pill, Diovan.

U.S. District Court Judge John D. Bates said in an opinion filed on Dec. 27, that the FDA did not act “capriciously” when it denied Mylan exclusivity to market its version of Diovan. Bates also said Mylan did not show it suffered “irreparable harm” as a result.

PITTSBURGH — Mylan has launched a generic drug used to treat sleep disorders, the company said Friday.

The generic drug maker announced the launch of modafinil tablets in the 100-mg and 200-mg strengths. The drug is a generic version of Provigil, made by Cephalon — a company that Teva Pharmaceutical Industries acquired last year — and used to treat narcolepsy, obstructive sleep apnea and shift work disorder.

PITTSBURGH — Generic drug maker Mylan has begun commercial operations in India, focusing on drugs to treat HIV and AIDS, the company said Monday.

The company is launching 18 antiretroviral drugs for HIV/AIDS in India, which has the world's third-largest population of people with the disease, according to the National AIDS Control Organization.

PITTSBURGH — "Buy me some peanuts and Cracker Jacks," goes the line from the famous baseball anthem. For some people, however, that innocuous lyric is a ticket to the hospital, or worse.

PITTSBURGH — Mylan has settled a patent litigation suit filed by Somaxon Pharmaceutical concerning an insomnia drug, Mylan said.

The generic drug maker said that under the settlement, it would have the right to sell doxepin hydrochloride tablets in the 3-mg and 6-mg strengths starting in January 2020. The drug is a generic version of Somaxon's Silenor.

PITTSBURGH — Mylan has launched generic versions of two drugs to treat bipolar disorder and allergies, the company said Tuesday.

Mylan announced the launch of lithium carbonate extended-release tablets in the 300-mg strength. The drug is a generic version of Noven Therapeutics' Lithobid, various versions of which had sales of about $21 million during the 12-month period ended in March, according to IMS Health.

PITTSBURGH — Mylan has launched a generic drug for treating thiamine deficiency, the company said Thursday.

The generic drug maker announced the launch of thiamine hydrochloride injection in the 100-mg-per-mL strength, packaged in 25-vial packs of 200-mg-per-2-mL multiple-dose vials.

The drug had sales of about $18.6 million during the 12-month period ended in March, according to IMS Health. Mylan said it would ship the drug immediately.

The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said. Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne. The company expects to launch it in the United States in fourth quarter 2012 under an agreement with Canada-based Cipher Pharmaceuticals.


PITTSBURGH — Mylan announced that its subsidiary has resolved all disputes with Teva pertaining to the sale of generic versions of a sleep disorder drug.

PITTSBURGH — A unit of generic drug maker Mylan has settled with Sunovion Pharmaceuticals over a drug used to treat chronic obstructive pulmonary disease and asthma.

Mylan announced Tuesday that it had reached a settlement in a patent litigation suit that Sunovion, which used to operate under the name Sepracor, had filed against Dey Pharma, now known as Mylan Specialty, concerning the drug Xopenex (levalbuterol hydrochloride).

PITTSBURGH and NEW YORK — The Drug Store News Group, the Pharmacist Society and Mylan Inc., one of the world's leading generics and specialty pharmaceutical companies, are pleased to announce an exclusive sponsorship to expand membership opportunities at PharmacistSociety.com — an online forum that supports and enhances professional networks for U.S.-based retail pharmacists, professional organizations and pharmacy companies.

BASKING RIDGE, N.J. — A company that makes an emergency treatment for severe allergic reactions is marking the 15th annual Food Allergy Awareness Week.

Mylan Specialty, a division of drug maker Mylan, said it would support various initiatives to raise awareness of life-threatening food allergies during the special week, which started Sunday and ends Saturday. Mylan Specialty is the maker of EpiPen (epinephrine), used to treat anaphylaxis, a severe allergic reaction that can occur quickly and without warning.